Adcendo

Investment area
Seed Investments
Region
Europe
Date of investment
April 2021

Adcendo ApS, a spin-out from the University of Copenhagen and Rigshospitalet and previously part of the BioInnovation Institute’s Creation House Program, is developing novel antibody-drug conjugates (ADCs) for treatment of cancers.

Adcendo

Investment area
Seed Investments
Region
Europe
Date of investment
April 2021

Adcendo ApS, a spin-out from the University of Copenhagen and Rigshospitalet and previously part of the BioInnovation Institute’s Creation House Program, is developing novel antibody-drug conjugates (ADCs) for treatment of cancers.

Adcendo

Investment area
Seed Investments
Region
Europe
Date of investment
April 2021

Adcendo ApS, a spin-out from the University of Copenhagen and Rigshospitalet and previously part of the BioInnovation Institute’s Creation House Program, is developing novel antibody-drug conjugates (ADCs) for treatment of cancers.